Evidence map›Paper›PMID 33057377›Full record

ArticlePloS one2020

Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB).

Tadashi Sofue, Naoki Nakagawa, Eiichiro Kanda, Hajime Nagasu, Kunihiro Matsushita, Masaomi Nangaku, Shoichi Maruyama, Takashi Wada, Yoshio Terada, Kunihiro Yamagata and 15 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Development of real-world evidence studies for hypertension in Japan.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Hyperuricemia: the third key player for nephrosclerosis with ischemia.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 2 countries.

Tadashi SofueDivision of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, Japan.ORCID 0000-0003-1136-8532
Naoki NakagawaDivision of Cardiology, Nephrology, Respiratory and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa, Japan.ORCID 0000-0002-5398-3667
Eiichiro KandaMedical Science, Kawasaki Medical School, Kurashiki, Japan.
Hajime NagasuDepartment of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Kunihiro MatsushitaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Masaomi NangakuDivision of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi WadaDepartment of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
Yoshio TeradaDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kochi, Japan.
Kunihiro YamagataDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hitoshi SugiyamaDepartment of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.ORCID 0000-0002-4127-6471
Takashi ShigematsuDepartment of Nephrology, Wakayama Medical University, Wakayama, Japan.
Takafumi ItoDivision of Nephrology, Faculty of Medicine, Shimane University, Izumo, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yoshitaka IsakaDepartment of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
Hirokazu OkadaDepartment of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Kazuhiko TsuruyaDepartment of Integrated Therapy for Chronic Kidney Disease, Kyushu University, Fukuoka, Japan.
Hitoshi YokoyamaDepartment of Nephrology, Kanazawa Medical University School of Medicine, Ishikawa, Japan.
Naoki NakashimaMedical Information Center, Kyushu University Hospital, Fukuoka, Japan.
Hiromi KataokaFaculty of Health Science and Technology, Kawasaki University of Medical Welfare, Kurashiki, Japan.
Kazuhiko OheDepartment of Healthcare Information Management, The University of Tokyo Hospital, Tokyo, Japan.
Mihoko OkadaInstitute of Health Data Infrastructure for All, Tokyo, Japan.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan.
Kawasaki Medical School · JPAsahikawa Medical University · JPJohns Hopkins University · USKagawa University · JPKanazawa Medical University · JPKanazawa University · JPKawasaki University of Medical Welfare · JPKōchi University · JPKyoto University · JPKyushu University · JPKyushu University Hospital · JPNagoya University · JPNiigata University · JPOkayama University · JPSaitama Medical University · JPShimane University · JPThe University of Osaka · JPThe University of Tokyo · JPUniversity of Tokyo Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Japan Chronic Kidney Disease Database (J-CKD-DB) is a nationwide clinical database of patients with chronic kidney disease (CKD) based on electronic health records. The objective of this study was to assess the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD.

methodsIn total, 35,508 adult outpatients with estimated glomerular filtration rates of 5-60 ml/min/1.73 m2 in seven university hospitals were included this analysis. The proportions of patients with CKD stages G3b, G4, and G5 were 23.5%, 7.6%, and 3.1%, respectively.

resultsLogistic regression analysis showed that prevalence of hyperuricemia was associated with CKD stages G3b (adjusted odds ratio [95% confidence interval]: 2.12 [1.90-2.37]), G4 (4.57 [3.92-5.32]), and G5 (2.25 [1.80-2.80]). The respective prevalences of hyponatremia, hypercalcemia, hyperphosphatemia, and narrower difference between serum sodium and chloride concentrations were elevated in patients with CKD stages G3b, G4, and G5, compared with those prevalences in patients with CKD stage G3a. The prevalences of hyperkalemia were 8.3% and 11.6% in patients with CKD stages G4 and G5, respectively. In patients with CKD stage G5, the proportions of patients with optimal ranges of serum uric acid, potassium, corrected calcium, and phosphate were 49.6%, 73.5%, 81.9%, and 56.1%, respectively.

conclusionsWe determined the prevalences of hyperuricemia and electrolyte abnormalities in Japanese patients with CKD using data from a nationwide cohort study.

Indexed as

AdolescentAdultAgedAged, 80 and overCross-Sectional StudiesDatabases, FactualElectrolytesFemaleGlomerular Filtration RateHospitals, UniversityHumansHyperuricemiaJapanMaleMiddle AgedPrevalenceElectrolytesUric Acid

Identifiers

PMID33057377
PMCPMC7561156
OpenAlexW3093402178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.